Hers, Hims and Super Bowl

Hims & Hers Stock Soars on Momentum From Super Bowl Ad, RFK Confirmation
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday as the company’s [controversial Super Bowl ad](
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims & Hers' Super Bowl ad turns up the heat on GLP-1 battle
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. | Hims & Hers hit the bullseye with its Super Bowl ad,
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Hims & Hers aired a Super Bowl ad for weight loss drugs. It alarmed health experts and senators.
In response to complaints made publicly by the Partnership for Safe Medicine and the Obesity Society, Hims & Hers provided Yahoo Life with the following statement: This is a clear attempt by industry groups to cancel an advertisement that directly calls out how they are part of a system that fails to prioritize the health of Americans.
Hims & Hers Set To Run Impactful Super Bowl Ad
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss offerings in a way that will generate buzz.
Hims & Hers stock sees another spike in trading days after Super Bowl ad
Telehealth stock Hims & Hers spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticize
Hims & Hers markets itself in a very 2025 way: by picking a fight
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Zacks.com on MSN5h
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.
Hims & Hers: Firing On All Cylinders, But Expensive
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Fortune11d
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
A still from the 2025 Super Bowl commercial “Sick of the System,” from telehealth company Hims & Hers. © 2024 Fortune Media IP Limited. All Rights Reserved. Use ...
Zacks.com on MSN13h
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Atlantic6d
What Is Hims Actually Selling?
Listen to more stories on the Noa app. The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales ...
Money Morning1d
HIMS Stock Surge: Is There Still Time to Buy Hims & Hers?
Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...
Zacks.com on MSN20h
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...